Marc Berger is Chief Executive Officer at Verana Health. He was previously Senior Vice President at Verana Health and a member of the core leadership team responsible for setting Verana Health’s corporate strategy. He served as the company’s General Counsel and Privacy Officer and was responsible for the company’s legal functions, including corporate, privacy, commercial contracting, health law, and intellectual property activities. As Senior Vice President, he also oversaw Verana Health’s Security & Compliance and People & Culture teams.
Prior to joining Verana Health, Marc was General Counsel at Flatiron Health, where he was a member of the four-person team that negotiated the $2.1B acquisition by Roche. Marc has also served as Vice President and Assistant General Counsel at Medidata Solutions, where he had global responsibility for negotiating agreements with life science companies and partners for Medidata’s clinical trial technology and service offerings.
Marc received his JD and MBA from the University of Miami School of Law, and his BS in Management and International Business from Penn State University.Marc Berger on LinkedIn
I love working at mission-driven companies. Verana’s deep commitment to improving patient care and accelerating scientific research with clinical data is something the entire organization is behind.
Matthew Roe, MD, MHS is Chief Medical Officer at Verana Health, where he leads the cross therapeutic medical team working to ensure the clinical validity and scientific integrity of the company’s research. Additionally, Dr. Roe leads Verana Health’s regulatory strategy, which focuses on determining how data curated by Verana Health can be utilized for regulatory decision-making. A cardiologist and clinical researcher, Dr. Roe joined Verana Health after spending two decades at the Duke University School of Medicine and the Duke Clinical Research Institute (DCRI), the world’s largest academic research organization. At Duke, he focused on research initiatives leveraging real-world data for observational and prospective studies. Dr. Roe was previously a co-principal investigator for the landmark ADAPTABLE trial and also held leadership positions with several diverse registries focusing upon the treatment and outcomes of patients with cardiovascular disease. At the DCRI, Dr. Roe was Senior Investigator as well as the Director of the organization’s Clinical Research Fellowship and Think Tank series.
Dr. Roe received his MD and MHS degrees from Duke University School of Medicine in 1993 and 2001, respectively. He completed an Internal Medicine residency at Duke University Medical Center in 1996 and a Cardiovascular Fellowship at the Cleveland Clinic Foundation in 1999.Matthew Roe, MD, MHS on LinkedIn
I joined Verana Health to contribute to our mission of leveraging real-world data to enable clinicians to provide the highest quality medical care, to improve the health and quality of life of patients across diverse medical conditions, and to catalyze a transformation of clinical research approaches and processes.
Marie-Eve Piche, Verana Health’s Chief Financial Officer, has nearly two decades of financial management experience in public and fast-growing private companies. Marie-Eve was previously the CFO of Pymetrics and built the financial strategy and capabilities that enabled a successful Series B fundraising. She also served as Vice President of Financial Planning and Analysis at AppNexus, where she helped grow revenue by more than six times during her tenure and was on the team that drove the $1.6B acquisition by AT&T. She began her career at General Electric, holding key financial roles at NBC Sports and Telemundo.
Marie-Eve received her dual MBA from Columbia University and London Business School. She also holds a Master’s in economics from McGill University and a B.Com. from H.E.C. Montreal.Marie-Eve Piche on LinkedIn
Verana Health is a company that is doing ground-breaking work with technology and data, and is being built by a team that works tirelessly to deliver against its commitment to patients. I'm thrilled to contribute to the impact I know this company will make.
Hylton Kalvaria is Chief Business Officer, leading Verana Health’s commercial organization, marketing, and major partnership initiatives with medical associations, life science companies, and regulatory bodies. Hylton joins Verana from Flatiron Health, where he founded, built and led the West Coast business, representing half of Flatiron’s commercial activity. In that capacity, Hylton’s team led the design and execution of Flatiron’s first regulatory-grade projects intended for influential stakeholder audiences, including the FDA. Hylton previously held a variety of roles at Genentech and was appointed to lead a CEO-sponsored initiative focused on identifying emerging sources of real-world data and utilizing those data across the Genentech organization, an initiative that led to Roche’s initial investment in Flatiron.
Hylton holds an MBA and BS in Economics from Duke University.Hylton Kalvaria on LinkedIn
I'm excited to make a big impact on how we generate evidence for new and existing drugs and devices. We have an opportunity to reinvent that process to be more patient and provider focused.
Ann Watson is Verana Health’s Senior Vice President of People and Culture, bringing a passion for building teams to Verana Health’s next phase of growth. The People & Culture team is responsible for all phases of the employee lifecycle: from finding great people to supporting their development all the way through to the alumni phase. Ann has over twenty years of experience in Human Resources and Talent Acquisition, primarily with small and mid-sized technology organizations. Ann was previously the Chief People Officer at MasterClass, at Varo Bank, and ran the Employee Experiences organization at Fandom. She specializes in growing teams from 50 to 500+, doubling the team multiple years in a row, building infrastructure to scale through the early start-up stage to mid-size maturity and beyond.
Ann has a BA from Santa Clara University and is a member of PeopleTechPartners, an organization devoted to accelerating solutions that drive the future of work.Ann Watson on LinkedIn
In addition to being drawn to the incredible mission of improving patient outcomes, the people are why I chose Verana. It is an incredible privilege to work with this team and I’m very appreciative of the overall lack of jerks. Verana is doing great work with great people!
Sonja Wustrack is Senior Vice President, Commercial Operations at Verana Health, where she brings over 20 years of health research experience, including academic research, public health surveillance, clinical trial technology, and clinical research. Within the biotechnology and pharmaceutical space, she has held positions in delivery, operations management, sales enablement leadership and account management. Most recently at IQVIA, Sonja focused on enhancing customer engagement and demonstrating improved value through for pharma, payors, providers and patients by leveraging real-world data and analytics to innovate clinical trial design and accelerate execution.
Sonja holds an MPH in Epidemiology from the Tulane School of Public Health, and a Bachelor’s degree in biology from Vassar College.Sonja Wustrack on LinkedIn
I am inspired by the mission to get the right medicines to patients, faster. At Verana, we have an unparalleled depth of real-world data, combined with the expert data insights and clinical expertise and supported by technology and advanced analytics, to be a partner in shifting the drug development paradigm by enabling acceleration through innovation.
Kirk Fjeldheim is Chief Information Security Officer, where he is responsible for Verana Health’s data, infrastructure and corporate protection strategies, which include identifying, developing, implementing, and maintaining processes across product and corporate systems. Kirk also manages corporate IT and Compliance. Kirk Fjeldheim brings several decades of experience at high-growth technology companies to Verana Health. Prior to joining Verana Health, Kirk was Chief Information Security Officer at Syapse, Inc. and Chief Information Officer at SugarCRM. As Vice President of IT and Security at Rally Health, he led Security, compliance and IT for more than 1,400 employees and developed and implemented HIPAA compliance and risk management efforts for a customer application reaching 38 million users. He has also held senior IT positions at Zynga, Xsigo Systems, Openwave Systems, and Siebel Systems.Kirk Fjeldheim on LinkedIn
Insights from health data are a critical component of improving the lives of people all over the world. I am thrilled to work at a company where technologists and data scientists are working together to improve quality of care and to advance medical research.
Chhaya Shadra is Vice President of Product Management, Data & Informatics, where she is responsible for leading product vision and strategy for data and informatics at Verana Health. Chhaya is an epidemiologist-informatician by training, bringing her deep understanding of systems engineering and user workflow to healthcare technology companies like Converge Health by Deloitte, Humedica by Optum, Syapse, Flatiron Health, and Verana Health. Chhaya’s recent work has focused on product, information architecture and ontology development for integrated precision research data platforms that are sourced from EHR, claims, pharmacy, and medical device data. These platforms are currently being used for real-world observational research, health economics and outcomes research (HEOR), and comparative effectiveness research (CER). Chhaya has focused her informatics career on interoperability and data integrity of routinely captured data that may be used secondarily.
Chhaya holds a Master’s in Health Informatics from Northeastern University and a Master’s in Health Sciences in Epidemiology from Pune University.Chhaya Shadra on LinkedIn
I’m passionate about innovation and outside the box thinking in healthcare. We have been following the same paradigms of research and evidence generation in healthcare for over half a century, even with the backdrop of technological innovation and vast amounts of data being captured for routine care. Verana’s mission of curating the largest sets of routinely captured specialty data in medicine to accelerate clinical research for the patient is exactly aligned with my personal passion and mission.
Aracelis Torres, PhD, MPH is Vice President of Quantitative Sciences where she oversees the quantitative sciences team working to develop and implement rigorous methodology to generate sound scientific evidence from real-world data. Dr. Torres is an epidemiologist with over ten years of academic and industry experience. Prior to joining Verana Health, she was a Director of Quantitative Sciences at Flatiron Health, where her work focused on translation of real-world oncology data to generate evidence. While at Flatiron Health, she led efforts related to the development of real-world endpoints, novel study designs, and prospective evidence generation while also serving as the Quantitative Sciences lead for the organization’s broader research collaboration with the FDA. She is also currently an Adjunct Professor at Columbia University Graduate School of Arts and Sciences, where she teaches a course on large-scale data processing and analysis.
Dr. Torres received a PhD in Cancer Epidemiology from Johns Hopkins Bloomberg School of Public Health, an MPH in Chronic Disease Epidemiology from Yale University’s School of Public Health, and a BS in Molecular, Cellular, and Developmental Biology from Yale University.Aracelis Torres, PhD, MPH on LinkedIn
Verana’s mission to rigorously generate insights from real-world data is both inspiring and exciting. It provides a unique opportunity to tackle some of the toughest challenges in clinical research while keeping patients at the forefront of our work.
Lindsey Karberg is Vice President of Marketing where she brings more than 15 years of experience leading groundbreaking marketing and digital innovation efforts for global healthcare organizations, including three successful start-ups.
Prior to joining Verana Health, Lindsey was the Vice President of Digital Strategy & Innovation at AbbVie where she led an internal digital incubator and innovation consulting arm supporting multiple therapeutic areas. Lindsey originally came to AbbVie (formerly Allergan) through the acquisition of ZELTIQ for $2.4B, leading the consumer and physician digital marketing and digital product strategy for the CoolSculpting brand, pre- and post-acquisition. Prior to that, Lindsey built and ran global digital and marketing communications at Natera, a Silicon Valley-based genetic testing company that went public ($180M IPO) during Lindsey’s time there. Before that, she oversaw digital and consumer marketing efforts for Ultherapy and Cellfina at Ulthera, Inc. to help position the company for a $600 million acquisition by Merz Pharmaceuticals. And, her love for digital health started at Amendola Communications, where she built the agency’s social media arm and supported the marketing and public relations outreach for healthcare information technology clients such as McKesson, Allscripts, RelayHealth, Sage, and more.
Lindsey holds a B.A. from Arizona State University and an M.S. from Boston University.Lindsey Karberg on LinkedIn
Data has the power to make a positive impact in healthcare. Working for a company that sits at the center of the healthcare data ecosystem is meaningful and motivating. I may not be a clinician, but working here, I, too, can play a role in changing and saving lives.
Kleiner, Perkins, Caufield & Byers
Verana Health and Lagunita Biosciences
Chief Executive Officer,
American Academy of Ophthalmology
Ahmanson Professor in Ophthalmology,
Stein Eye Institute, UCLA
Chief Executive Officer,
American Urological Association
American Academy of Neurology
Co-Founder and Managing Director,
Biomatics Capital Partners
Chief Investment Officer and Founder,
Verana Health is backed by leading institutional investors and industry veterans:
Brook Byers, founding member and senior partner of Kleiner, Perkins, Caufield, and Byers.